138148-35-3

Basic information

• Product Name: PANTETHINE
• Synonyms: Propionamide, N,N'-(dithiodiethylene)bis[3-(2,4-dihydroxy-3,3-dimethylbutyramido)- (5CI);Butanamide, N,N'-[dithiobis[2,1-ethanediylimino(3-oxo-3,1-propanediyl)]]bis[2,4-dihydroxy-3,3-dimethyl- (9CI)
• CAS NO: 138148-35-3
• Molecular Formula: C₂₂H₄₂N₄O₈S₂
• Molecular Weight: 554.72088
• EINECS: 240-842-8
• Mol File: 138148-35-3.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 987.2°C at 760 mmHg
• Flash Point: 550.8°C
• Appearance: /
• Density: 1.277g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.56
• CAS DataBase Reference: PANTETHINE(CAS DataBase Reference)
• NIST Chemistry Reference: PANTETHINE(138148-35-3)
• EPA Substance Registry System: PANTETHINE(138148-35-3)

Safety Data

• Hazardous Substances Data: 138148-35-3(Hazardous Substances Data)

Usage

General Description

Pantethine is a chemical compound derived from pantothenic acid, or vitamin B5, and is used primarily for its potential therapeutic effects on cardiovascular health and cholesterol levels. It is a precursor to coenzyme A, an essential enzyme involved in numerous metabolic pathways in the body, and is thought to positively impact lipid metabolism, helping to lower levels of LDL cholesterol and triglycerides while increasing levels of HDL cholesterol, or "good" cholesterol. Additionally, pantethine has been suggested to have antioxidant and anti-inflammatory properties, potentially benefiting overall heart health. Preliminary research has also indicated potential benefits for liver function and blood sugar regulation. However, further clinical studies are needed to confirm these effects and establish optimal dosages for therapeutic use.

InChI:InChI=1/C22H42N4O8S2/c1-21(2,13-27)17(31)19(33)25-7-5-15(29)23-9-11-35-36-12-10-24-16(30)6-8-26-20(34)18(32)22(3,4)14-28/h17-18,27-28,31-32H,5-14H2,1-4H3,(H,23,29)(H,24,30)(H,25,33)(H,26,34)/t17-,18-/m0/s1

Upstream product

• 646-08-2 N-mercaptoethyl-3-aminopropionamide disulfide 
• 599-04-2 (R)-Pantolacton 
• 87503-54-6 bis-{2-[(N,N-phthaloyl-β-alanyl)-amino]-ethyl}-disulfide 
• 60-23-1 Cysteamine 
• 51-85-4 2,2'-dithio-bis[ethylamine] 
• 137-08-6 calcium (R)-pantothenate 
• 79-83-4 pantothenic acid 
• 55512-69-1 pantetheine 

Downstream Products

• 2226-71-3 D‐pantetheine 4'‐phosphate 
• 1285527-20-9 C₅₂H₉₂N₆O₁₀S₂Si₂ 
• 1285527-13-0 neamine 6'-N-(R)-(3-((2-((2-amino-2-oxoethyl)thio)ethyl)-amino)-3-oxopropyl)-2-hydroxy-3,3-dimethyl-4-(3-oxobutanamido)butanamide 
• 1285527-14-1 neamine 6'-N-(R)-(3-((2-((2-amino-2-oxoethyl)thio)ethyl)amino)-3-oxopropyl)-4-(N-benzyl-3-oxobutanamido)-2-hydroxy-3,3-dimethylbutanamide 
• 1285527-15-2 neamine 6'-N-(R)-(3-((2-((2-amino-2-oxoethyl)thio)ethyl)amino)-3-oxopropyl)-2-hydroxy-3,3-dimethyl-4-(3-oxo-N-phenethylbutanamido)butanamide 
• 1285527-16-3 neamine 6'-N-(R)-(3-((2-((2-amino-2-oxoethyl)thio)ethyl)-amino)-3-oxopropyl)-2-hydroxy-3,3-dimethyl-4-(3-oxo-N-(3-phenylpropyl)butanamido)butanamide 

Related news

PANTETHINE (cas 138148-35-3) stimulates lipolysis in adipose tissue and inhibits cholesterol and fatty acid synthesis in liver and intestinal mucosa in the normolipidemic rat08/25/2019

In vitro effects of pantethine on adipose tissue lipolysis and on both hepatic and intestinal cholesterol and fatty acid synthesis in normolipidemic rats are determined and related to their respective in vivo hypolipidemic effects after acute oral administration. At 3, 5, 7 and 24 h after a sing...detailed

Research paperEffects of PANTETHINE (cas 138148-35-3) on in-vitro peroxidation of low density lipoproteins☆08/23/2019

The effects of pantethine on LDL peroxidation in vitro are reported. LDL isolation by density gradient ultracentrifugation from 12 normal subjects were dialyzed 48 h under conditions allowing oxidation. The LDL peroxides were assayed for the presence of malondialdehyde (MDA) on the lipoprotein. ...detailed

Reduction of PANTETHINE (cas 138148-35-3) in rabbit ocular lens homogenate08/20/2019

In several animal models, preliminary studies have indicated that pantethine may inhibit cataract formation. Therefore, preclinical trials need to be conducted to study the pharmacology of pantethine in the ocular lens and to establish its efficacy. Since pantethine, which is a disulfide, can un...detailed

Original ArticleEfficacy and tolerability of coenzyme A vs PANTETHINE (cas 138148-35-3) for the treatment of patients with hyperlipidemia: A randomized, double-blind, multicenter study08/18/2019

BackgroundNew, safer, and more effective agents to treat hyperlipidemia and thereby prevent cardiovascular events are under research.detailed

Original articleComparison of the effects of PANTETHINE (cas 138148-35-3) and fursultiamine on plasma levels of adrenocorticotropic hormone and neuropeptide Y under continual stress exposure08/17/2019

Some abnormalities of gastrointestinal function are presumed to result from changes in levels of stress-related hormones from the hypothalamic-pituitary-adrenal (HPA) axis and sympathetic nervous system (SNS), represented by adrenocorticotropic hormone (ACTH) and neuropeptide Y (NPY), respective...detailed

Relevant articles and documents

-

-

An Efficient Chemoenzymatic Synthesis of Coenzyme A and Its Disulfide

We have developed a chemoenzymatic route to coenzyme A (CoASH) and its disulfide that is amenable to gram-scale synthesis using standard laboratory equipment. By synthesizing the symmetrical disulfide of pantetheine (pantethine), we avoided the need to mask the reactive sulfhydryl and also prevented sulfur oxidation byproducts. No chromatography is required in our synthetic route to pantethine, which facilitates scale-up. Furthermore, we discovered that all three enzymes of the CoASH salvage pathway (pantetheine kinase, phosphopantetheine adenyltransferase, and dephospho-coenzyme A kinase) accept the disulfide of the natural substrates and functionalize both ends of the molecules. This yields CoA disulfide as the product of the enzymatic cascade, a much more stable form of the cofactor. Free CoASH can be prepared by in situ S-S reduction.